pCAG-H2B-GFP
(Plasmid
#184777)
-
PurposeExpresses H2B-GFP in human pluripotent stem cells
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 184777 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepCAG
- Total vector size (bp) 7625
-
Vector typeMammalian Expression
-
Selectable markersPuromycin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberLow Copy
Gene/Insert
-
Gene/Insert nameH2BC11
-
Alt nameHuman histone H2B
-
Alt nameH2BJ; H2B/r; H2BFR; HIST1H2BJ
-
SpeciesH. sapiens (human)
-
Insert Size (bp)380
-
GenBank IDX00088
-
Entrez GeneH2BC11 (a.k.a. H2B/r, H2BFR, H2BJ, HIST1H2BJ)
-
Tag
/ Fusion Protein
- EGFP (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site KpnI (unknown if destroyed)
- 3′ cloning site BamHI (unknown if destroyed)
- 5′ sequencing primer CMV-F
- 3′ sequencing primer EGFP-N (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
-
A portion of this plasmid was derived from a plasmid made byAddgene plasmid #11680
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
H2B-EGFP sequence from plasmid #11680 was excised at NheI and NotI sites and ligated into pCAG vector with compatible overhangs.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pCAG-H2B-GFP was a gift from Ivana Barbaric (Addgene plasmid # 184777 ; http://n2t.net/addgene:184777 ; RRID:Addgene_184777) -
For your References section:
Assessing Cell Competition in Human Pluripotent Stem Cell (hPSC) Cultures. Price CJ, Barbaric I. Curr Protoc. 2022 May;2(5):e435. doi: 10.1002/cpz1.435. 10.1002/cpz1.435 PubMed 35621694